Introduction: The Persistent Challenge of PASC
Postacute sequelae of SARS-CoV-2 infection (PASC), colloquially known as Long COVID, has emerged as a significant public health crisis following the global pandemic. Characterized by a constellation of symptoms including fatigue, cognitive dysfunction, and respiratory issues that persist long after the initial infection, PASC affects millions worldwide. Despite its prevalence, the medical community has struggled to identify evidence-based pharmacological interventions to alleviate these symptoms. The search for effective treatments has led researchers to investigate repurposed drugs with known safety profiles and potential mechanistic relevance to the pathophysiology of PASC.
